Protocol: does sodium nitrite administration reduce ischaemia-reperfusion injury in patients presenting with acute ST segment elevation myocardial infarction? Nitrites in acute myocardial infarction (NIAMI) by Siddiqi, Nishat et al.
Siddiqi et al. Journal of Translational Medicine 2013, 11:116
http://www.translational-medicine.com/content/11/1/116PROTOCOL Open AccessProtocol: does sodium nitrite administration
reduce ischaemia-reperfusion injury in patients
presenting with acute ST segment elevation
myocardial infarction? Nitrites in acute myocardial
infarction (NIAMI)
Nishat Siddiqi1, Margaret Bruce1, Christopher J Neil1, Baljit Jagpal1, Graeme Maclennon2, Seonaidh C Cotton2,
Sofia A Papadopoulo3, Nicholas Bunce4, Pitt Lim4, Konstantin Schwarz1, Satnam Singh1, David Hildick-Smith5,
John D Horowitz6, Melanie Madhani7, Nicholas Boon8, Juan-Carlos Kaski3, Dana Dawson1
and Michael P Frenneaux1*Abstract
Background: Whilst advances in reperfusion therapies have reduced early mortality from acute myocardial
infarction, heart failure remains a common complication, and may develop very early or long after the acute event.
Reperfusion itself leads to further tissue damage, a process described as ischaemia-reperfusion-injury (IRI), which
contributes up to 50% of the final infarct size. In experimental models nitrite administration potently protects
against IRI in several organs, including the heart. In the current study we investigate whether intravenous sodium
nitrite administration immediately prior to percutaneous coronary intervention (PCI) in patients with acute ST
segment elevation myocardial infarction will reduce myocardial infarct size. This is a phase II, randomised, placebo-
controlled, double-blinded and multicentre trial.
Methods and outcomes: The aim of this trial is to determine whether a 5 minute systemic injection of sodium
nitrite, administered immediately before opening of the infarct related artery, results in significant reduction of IRI in
patients with first acute ST elevation myocardial infarction (MI). The primary clinical end point is the difference in
infarct size between sodium nitrite and placebo groups measured using cardiovascular magnetic resonance
imaging (CMR) performed at 6–8 days following the AMI and corrected for area at risk (AAR) using the endocardial
surface area technique. Secondary end points include (i) plasma creatine kinase and Troponin I measured in blood
samples taken pre-injection of the study medication and over the following 72 hours; (ii) infarct size at six months;
(iii) Infarct size corrected for AAR measured at 6–8 days using T2 weighted triple inversion recovery (T2-W SPAIR or
STIR) CMR imaging; (iv) Left ventricular (LV) ejection fraction measured by CMR at 6–8 days and six months
following injection of the study medication; and (v) LV end systolic volume index at 6–8 days and six months.
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Funding, ethics and regulatory approvals: This study is funded by a grant from the UK Medical Research
Council. This protocol is approved by the Scotland A Research Ethics Committee and has also received clinical trial
authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) (EudraCT number:
2010-023571-26).
Trial registration: ClinicalTrials.gov: NCT01388504 and Current Controlled Trials: ISRCTN57596739
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There are approximately 125,000 acute myocardial in-
farctions (AMI) in the UK per year (BHF statistics 2008
(www.heartstats.org)). Whilst advances in reperfusion
therapies such as primary percutaneous coronary angi-
ography (PPCI) have reduced early mortality from AMI
[1] morbidity, most commonly resulting from heart
failure, which may occur early or long after the MI,
remains high [2]. Paradoxically, the act of reperfusion
leads to further tissue damage, a process described as
ischaemia-reperfusion-injury (IRI) which can account for
up to 50% of the final infarct size [3]. Given that infarct
size is determined not only by ischaemia but also by IRI,
targeting the latter offers the potential to limit myocar-
dial injury and reduce mortality and morbidity.
Ischaemia reperfusion injury and conditioning
Following reperfusion of an occluded artery, a cascade of
events leads ultimately to the opening of the mitochon-
drial transition pore (MTP) in the inner mitochondrial
membrane. Factors promoting opening of the MTP in-
clude an increase in intracellular calcium that occurs
during ischaemia and increased generation of reactive
oxygen species (ROS) and toxic aldehydes [4]. The open-
ing of the MTP leads to irreversible cell death. This re-
sults from both acute energetic impairment (due to loss
of the electrochemical gradient across the mitochondrial
membrane that drives ATP synthesis) and release of the
mitochondrial contents into the cytosol, including cyto-
chrome C, which activates pro-apoptotic pathways [5].
Crucially, the opening of the MTP does not occur until
approximately two to three minutes after reperfusion.
This is because the low pH that is present during ischae-
mia inhibits its opening, and it is not until the pH starts
to recover following reperfusion that the raised calcium
and ROS induce opening of the MTP.
In 1986 Murry and colleagues [6] made the seminal ob-
servation that brief repeated episodes of myocardial ischae-
mia reduced the magnitude of myocardial injury caused by
a subsequent prolonged episode of coronary occlusion, a
phenomenon they termed ischaemic preconditioning and
which has since been reproduced in well over 1000 papers[7-9]. Several endogenous conditioning pathways confer
cardio-protection against IRI including the Reperfusion
Injury Salvage Kinase Pathway (RISK). Ultimately these act
by inhibiting the opening of the MTP [7,10]. A corollary of
the fact that MTP opening is delayed by some minutes
after reperfusion is the potential to reduce IRI by interven-
tions delivered either during ischaemia (perconditioning)
or at the time of reperfusion (postconditioning). Thus,
graded opening of an occluded coronary artery reduces IRI
(direct postconditioning). Subsequent studies have shown
that brief periods of ischaemia in other organs confer simi-
lar protection to the myocardium, a phenomenon called
remote ischemic myocardial conditioning [11]. ‘Ischaemic
conditioning’ may be replicated by using several pharmaco-
logical stimuli, e.g. opiates, cyclosporine, erythropoietin,
H/Na exchange inhibitors and nitric oxide donors. Both is-
chaemic and pharmacological cardiac pre-conditioning are
mediated at least in large part via the RISK pathway [10].
There is extensive literature on successful pre, per and
post conditioning interventions in animal models of
AMI, which have resulted in reduction in final infarct
size by up to 50%. Unfortunately, in spite of these very
promising results in animal models, translation into
benefit in human studies has been inconsistent. There
may be several reasons for the poor translation into
humans: (i) patients have multiple comorbidities that
may make the heart more resistant to conditioning (e.g.
age, hypertension and diabetes) [12,13]; (ii) prompt re-
perfusion with PPCI may minimise the potential benefit
from conditioning strategies. Indeed, there is evidence
from some of the human intervention studies that the
benefit is largely confined to patients with larger infarcts,
particularly those associated with occlusion of the left
anterior descending artery [14]; (iii) it is known that spon-
taneous opening and closing of the occluded coronary
artery (intermittency) is common in acute myocardial
infarction [15], potentially replicating direct post condi-
tioning and in this context any additional conditioning
intervention may have limited therapeutic impact.
Nevertheless positive studies in humans have been
reported. Remote (forearm) ischaemic perconditioning
in acute ST elevation MI (STEMI) (administered in the
Siddiqi et al. Journal of Translational Medicine 2013, 11:116 Page 3 of 8
http://www.translational-medicine.com/content/11/1/116ambulance en route to hospital for PPCI) resulted in a
reduction in IRI – expressed as an increase in myocar-
dial salvage compared to a placebo intervention. Al-
though this did not translate into a significant reduction
in infarct size for the whole group, a reduced infarct size
was seen in the subgroup of patients with left anterior
descending coronary artery occlusions [14]. Pharmaco-
logical postconditioning using cyclosporine administered
prior to PPCI in acute STEMI was reported to decrease
the area under the curve for the biomarkers creatine
kinase (CK) and Troponin (the primary end point) and a
reduction in infarct size (assessed by gadolinium late
enhancement on cardiovascular magnetic resonance
imaging (CMR) performed at five days) was reported in
a subgroup of 27 patients [16].Nitrite, NO and cardioprotection
Plasma nitrite is derived from oxidation (principally by
Caeruloplasmin) of endothelially derived nitric oxide
(NO), and by the reduction of dietary inorganic nitrate
by bacteria in the salivary glands and gastro-intestinal
tract [17]. Under normoxic conditions, nitrite has a rela-
tively modest vasorelaxant effect compared to organic
nitrates. However in vascular rings highly acidic solu-
tions of nitrite causes marked vasorelaxation [18], largely
due to reduction to NO by acid disproportionation.
Under less extreme conditions modest hypoxia and/or
acidosis results in reduction of nitrite to NO by various
mechanisms including by mitochondrial aldehyde de-
hydrogenase type 2 (ALDH2) [19], cytochrome C [20],
deoxygenated forms of heme proteins including haemo-
globin and myoglobin [21] endothelial nitric oxide syn-
thase, and xanthine oxidoreductase [22]. Consequently
nitrite induced vasodilation is potentiated by hypoxia
in vivo [23].
In addition to these vascular effects a number of studies
in animal models have now shown that sodium nitrite ad-
ministered acts as both a pre and a per-conditioning agent
[24]. This effect appears to be at least in part due to reduc-
tion of nitrite to NO by deoxymyoglobin in the heart, and
can be abolished by NO scavengers [25,26]. Low dose
nitrite given at the time of commencing resuscitation in a
mouse model of cardiac arrest improved both cardiac and
neurological function and increased survival [27].
In a study of acute MI in a canine model, an infusion
of sodium nitrite administered during coronary occlu-
sion (i.e. a perconditioning regime) conferred significant
cardioprotection. Pertinently, there was no significant
difference in cardioprotection between a group that re-
ceived an infusion of sodium nitrite during the final five
minutes of the two hour coronary occlusion and that
seen in a group having an infusion throughout the final
60 minutes of the occlusion [28].Trial design and methods
NIAMI is a UK Medical Research Council funded, multi-
centre, double blind, placebo-controlled, randomised trial
evaluating sodium nitrite versus placebo. The trial will be
conducted in cardiac units in three UK hospitals - Aberdeen
Royal Infirmary, St George’s Hospital London and Brighton
and Sussex University Hospitals NHS Trust and at the
Queen Elizabeth Hospital, Adelaide, Australia.
See Figure 1 for an overview of the trial design.
Trial hypothesis
The hypothesis being tested is: A five minute systemic
injection of sodium nitrite, administered immediately
before opening of the infarct related artery by PPCI, re-
sults in a significant reduction of IRI in patients with
first acute STEMI.
Active treatment
Sterile solution containing 70 micromol sodium nitrite
dissolved in 5 ml water injected intravenously over a
period of five minutes.
Placebo
Sterile solution containing 0.9%w/v sodium chloride in
5 ml water injected intravenously over a period of five
minutes.
Selection of participants
As standard practice, clinicians will assess patients pre-
senting with chest pain. Those patients who are potentially
eligible will be logged using the inclusion form. Those
who are found to be not eligible will have the reason for
non-eligibility recorded on the same form.
Inclusion criteria
Men aged ≥18 years, women aged ≥55 years, and
women <55 years who are sterilised, or have had a
hysterectomy or have effective contraception and
therefore with no possibility of being pregnant;
Presenting within 12 hours of the onset of chest pain
and with ECG findings of ST segment elevation of
more than 1mm in two contiguous limb leads or 2mm
elevation in two contiguous chest leads or new left
bundle branch block (LBBB) and for whom the clinical
decision has been made to treat with primary PCI;
Patients with posterior infarcts with anterior ST
segment depression who meet the other inclusion
criteria can also be included;
Occlusion of the culprit related artery (TIMI grade 0 or
TIMI grade 1);
Of North European descent.
Coronary angiogram performed
Clinical staff confirm eligibility on diagnostic angiogram
Randomise by selecting next available drug pack
Intravenous injection of 70 
micromoles sodium nitrite 
Intravenous injection of 
placebo
Blood samples at 
6, 12, 18, 24, 36, 48, 
60 and 72 hours
MRI at 6-8 days
MRI at 6 months
Blood samples at 
6, 12, 18, 24, 36, 48, 
60 and 72 hours
MRI at 6-8 days
MRI at 6 months
Opening of infarct related 
artery and PCI
Opening of infarct related 
artery and PCI
When full capacity has 
returned, seek fully informed 
consent 
Patient presents with MI
Any expression of 
doubt/ hesitation taken 
as refusal to 
participate; proceed 
with angiogram & PCI
Not eligible - excluded
Not eligible - excluded
In emergency situation:
Gain verbal agreement 
Pre-injection (baseline) blood sample
Where possible: Follow formal 
consent process using Brief 
Information Sheet and Initial 
Informed Consent Form
Clinical staff undertake initial screen for eligibility
When full capacity has 
returned, seek fully informed 
consent 
Figure 1 Overview of trial design.
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Historical or ECG evidence of previous myocardial
infarction;
Patients with prior coronary artery bypass grafting
(CABG);
Prior revascularisation procedure where this procedure
(PCI) was performed in the same territory as the
current infarct;
Known or suspected pregnancy;
Contra-indications to CMR;
Patients with cardiac arrest or cardiogenic shock;
Patients with left main coronary occlusion;
Patients with known moderate to severe renal failure
(estimated GFR < 30mls/min), or liver failure;
Patients undergoing rescue PCI for failed thrombolysis;
Patients with Left Main stenosis of such severity that
after PCI of their culprit lesion (LAD or LCx or RCA)they are likely to require CABG within the time course
of the study period (6 months).
Informed consent
Where possible, formal consent will be obtained prior to
including the patient in the trial. The brief information
sheet will be provided to patients, and they will be asked
to sign an initial consent form if they agree to take part
(initial informed consent). However, because this initial
consent may not be “fully” informed (either because
patients have had opiates to relieve pain or are in a state
of considerable anxiety), fully informed consent will be
sought from these patients when full capacity has
returned. At that stage, patients will receive full written
information and an explanation of the study. If they are
happy to remain part of the study, they will be asked to
sign the consent form. However, in the emergency
situation when there is no time to follow the initial
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treatment within the necessary time-window precludes
any reasonable attempt to obtain informed consent from
a relative or ‘legal representative’, verbal agreement will
be sought from the patient by the treating cardiologist
by providing a short spoken explanation. In deciding our
policy for seeking only verbal agreement, we have taken
full account of the provisions in The Medicines for
Human Use (Clinical Trials) Amendment (No 2) Regula-
tions 2006, section 31 of Mental Capacity Act (2005) and
part 5 of The Adults with Incapacity (Scotland) Act 2000.
In the Australian site, participants are asked to sign an
informed consent form prior to inclusion in the study.
Randomisation
Eligible participants will be randomised to the interven-
tion group or the placebo group on a 1:1 basis. The drug
packs (sodium nitrite and placebo) will be manufactured
by Tayside Pharmaceuticals. They will be randomised in
permuted blocks prior to dispatch to sites. Each drug
pack will be allocated a sequential number. At each site,
the next available drug pack will be selected and used
for eligible patients who give verbal agreement. The
number of the drug pack will be recorded on the inclu-
sion form and in the medical records.
Code break/emergency unblinding
There will be no facility for emergency unblinding.
There are two clinical reasons for this decision. Firstly,
there is no antidote to the study medication. Secondly,
knowledge of the treatment received (sodium nitrite or
placebo) would not impact on any management deci-
sions being taken if an adverse event occurs.
Description and justification of route of administration,
dosage, treatment periods
The dose of sodium nitrite is 70 micromoles sodium ni-
trite dissolved in 5ml water given intravenously over five
minutes immediately prior to opening of the infarct
related artery. This dose is based on a canine study in
which nitrite was infused during myocardial ischaemia,
but increased to reflect differences in body weight be-
tween this canine model and an average 70kg human
[28]. Nitrite has been used for decades as an antidote to
cyanide poisoning by inducing methaemoglobinemia
[29]. Physiological levels of methaemoglobin within the
blood vary from 0-2% [30]. Levels of up to 20% are consid-
ered safe in a clinical context [31]. The dose employed in
this study is not associated with methaemoglobinaemia
[32], although as a precaution patients whose ethnic origin
could indicate a high risk of G6PD deficiency will be
excluded. This dose has also been shown not to produce
significant change in blood pressure in either healthycontrols or patients with heart failure (Frenneaux, unpub-
lished data).
Study end points
Primary end point
(i) The difference in infarct size between sodium nitrite
and placebo groups measured using CMR performed 6–8
days following the acute myocardial infarction (assessed as
extent of late gadolinium enhancement (LGE) and
corrected for myocardial area at risk (AAR), which will be
assessed by epicardial extension of the LGE area (Endo-
cardial surface area - ESA).
Secondary end points
(i) Plasma CK and Troponin I area under curve
measured in blood samples taken pre-injection of
the study medication and at eight time-points over
the 72 hours following injection of the study
medication;
(ii) CMR measured Infarct size at 6–8 days with AAR
measured by T2 weighted triple inversion recovery
(T2-W SPAIR or STIR) CMR as a covariate;
(iii) AAR measured at 6–8 days using T2 weighted
triple inversion recovery (T2-W SPAIR or STIR)
CMR imaging;
(iv) LV ejection fraction measured by CMR at one week
and at six months after AMI;
(v) LV end systolic volume index at approximately one
week and at six months after AMI;
(vi) Infarct size (CMR) at six months post AMI.
Clinical and safety outcomes will be assessed for the
six months following MI (e.g. death, re infarction, fur-
ther re vascularisation, heart failure, stroke).
Timing and recording of safety parameters
The number and nature of any serious adverse events in
each arm will be recorded. Any serious adverse reactions
are likely to occur in the hours following administration
of the study drug and not in the following days/weeks.
Information regarding safety parameters will be collected
until hospital discharge and again at six months. A sum-
mary of all serious adverse reactions will be prepared
every three months and distributed to the participating
investigators, the Co-Sponsors, the manufacturer, the
Trial Steering Committee and the Data Monitoring
Committee (DMC).
A Developmental Safety Update Report will be prepared
annually and submitted to the MHRA Ethics Research
Committee in accordance with the guidance on annual
safety reporting. The DMC will convene regularly (at least
annually) and assess the safety of trial participants and the
completeness of data collected. Due to the timing of the
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pated the NIAMI trial be terminated for efficacy or futility.
However the DMC may advise that the trial is temporarily
or permanently halted based on safety concerns according
to the criteria defined in the DMC charter.
Assessment of end-points
Assessment of the end points will be performed blinded
to the treatment.
Blood samples/testing
Collection of samples
Blood samples will be collected pre-injection of the
study medication, and at 6, 12, 18, 24, 36, 48, 60 and 72
hours after injection of the study medication.
Blood analysis
Standard protocols for the analysis of plasma CK (Siemens
Advia 2400) and troponin I (Siemens Advia Centaur using
the TNI ultra method) will be used. All samples will be
tested at the core laboratory at the Aberdeen Royal
Infirmary.
CMR scanning/analysis
Patients found to have contraindications to CMR scan-
ning will not undergo this.
Scanning process
Scan 1: At 6–8 days post-injection of the study medication:
Gadolinium-enhanced CMR Imaging will be performed
to obtain the following measurements for analysis using
the parameters below:
 Volumetric LV ejection fraction
 Area at risk (ESA and oedematous area)
 Early assessment of infarct size and extent of
microvascular obstruction
 LV end systolic volume index
In addition a clinical CMR report will be produced for
the patient’s cardiologist.
Scan 2: At six months post-injection of the study medi-
cation: However in those patients in whom further
revascularisation or device (pacemaker/ICD) is planned be-
fore six months, the second CMR will be brought forward,
if necessary to as early as 3–4 months. CMR Imaging will
be performed to obtain the following measurements for
analysis using the parameters below:
 Late assessment of infarct size by LGE
 LV ejection fraction
 LV end systolic volume indexIn addition a clinical CMR report will be produced for
the patient’s cardiologist.Imaging parameters
The sequences will be standardised between centres as
much as possible (given that different vendor equipment
is available in one centre) but the individual scan param-
eters will be adapted according to the individual needs
of each patient (for example to match their heart rates).
Images will be stored locally following standard clinical
practice and transferred to the core lab in Aberdeen for
analysis.Analysis of images
All images will be analysed off line by a blinded observer
in the core lab using software already developed for this
purpose. A second blinded observer analysed a sample
of 40 images. Analysis of AAR will be performed on the
basis of two techniques described below. The first tech-
nique relates the length of the subendocardial edge of
the gadolinium boundary to the transmural volume of
left ventricular myocardium that this underlies (ESA
technique) [33]. The rationale of this is that infarction
begins in the subendocardial region and extends as a
wavefront transmurally; therefore salvage has the effect
of limiting this transmural extension. In the second
technique the area of oedema is measured using a T2
weighted triple inversion recovery (T2-W SPAIR or
STIR) CMR imaging. Oedema develops in the territory
supplied by an occluded artery within one hour of occlu-
sion [34]. In 40 NIAMI patients, we demonstrated a
median area at risk that was quantatively similar using
T2-W oedema and ESA methods but both within and
between observer variability was substantially better for
ESA (intra-class correlation for ESA was 0.96 and for T2
0.6). Accordingly, we chose to employ ESA for measure-
ment of AAR in the primary end point but retained T2 as
an area at risk measurement in the secondary end points.
The infarcted area will be identified from the LGE
CMR scan. The infarcted myocardium has conspi-
cuous demarcation on LGE and exquisite contrast
compared to the adjacent (nulled) myocardium, there-
fore tracing the infarct borders poses no problem for
analysis. Both the oedematous and infarcted areas will be
traced on all short axis slices and the total respective vol-
umes of oedematous/infarcted myocardium calculated in
absolute and relative terms to the left ventricular
volume using commercially available software (SEG-
MENT). Volumetric LV ejection fraction will be mea-
sured at the initial CMR scan and at six months using
standard approaches and commercially available soft-
ware (CMRTools, Cardiovascular Imaging Solutions,
London, UK).
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Proposed sample size
The primary outcome measure in this study will be the
infarct size. We will estimate the difference in infarct
size between the treatment and intervention group
correcting for area at risk (AAR) and diabetic status
using an analysis of covariance framework (ANCOVA)
to take advantage of the correlation between IS and
AAR to reduce sample size. Data from Cook (personal
communication) and the Aarhus study [14] suggest that
the AAR in this cohort would be approximately mean
30% (standard deviation 15), and that the IS in the pla-
cebo group should be between mean 15% (from Aarhus)
to 20% (from Cook) (standard deviation 11). We have
chosen the lower of these values because this estimate
was from clinical trial data. Data from both these data
sets indicate that correlation between AAR and IS is
above 0.60. The estimate of treatment effect in the
Aarhus study was a reduction of IS from 15% in the con-
trol to approximately 9% in the intervention group, a
reduction of 6%. This trial proposes more conservative,
but still clinically relevant treatment effect size of 4% be-
tween the treatment and control group (a standardised
effect size of about 0.36).
To explore statistical power and estimate sample size
for the trial we used Monte Carlo simulation in Stata 11.
(StataCorp. 2009. Stata Statistical Software: Release 11.
College Station, TX: StataCorp LP.) A model based the
above assumptions was used to simulate 10,000 trial data
sets for a variety of sample sizes. The simulated data sets
were analysed using ANCOVA to reflect the primary
trial analysis. The proportion of simulated trials that re-
turn p-values less than 0.05 was then counted to evalu-
ate the power of ANCOVA. A sample size of 150 (75
per group) will provide 90% power to detect a difference
of 4% between treatment and control group in IS
corrected for AAR. The sample size has been expanded
by approximately 30-35% to account for loss of outcome
measure due to death, those who decline CMR or are
unsuitable for CMR due to renal dysfunction and those
in whom the CMR scans are technically inadequate. We
therefore plan to recruit 200–210 participants.
Statistical analysis
Data will summarised and reported in adherence with
CONSORT guidelines. The analysis of the primary out-
come (IS) will use a generalised linear model (ANCOVA),
with covariates for area at risk, diabetic status and centre.
Only participants that have primary outcome data will be
included in the analysis, no attempt will be made to
impute data for participants that cannot, for whatever
reason, contribute CMR data in the primary analysis. We
will test the robustness of results to missing data by
conducting sensitivity analyses to suit the pattern of missingdata that arises. Secondary analyses will be conducted in a
similar manner, using models suitable for the outcome.
Blood sample outcomes will be analysed by first deriving an
area under the curve and then using a similar strategy
to the primary outcome. All estimates of effect will be
presented with 95% confidence intervals. All analyses
will be done in Stata (StataCorp. 2009. Stata Statistical
Software: Release 11. College Station, TX: StataCorp LP.)
Trial oversight committees
Data Monitoring Committee (DMC)
The DMC includes three independent members, inclu-
ding an independent statistician. The committee will
meet regularly to monitor the unblinded trial data and
serious adverse events and make recommendations as to
any modifications that are required to be made to the
protocol or the termination of all or part of the trial.
Trial Steering Committee (TSC)
The TSC includes three independent members. The com-
mittee will meet regularly to provide oversight for the trial.
Ethics and regulatory approvals
This protocol and related documents have been reviewed
by Scotland A Research Ethics Committee. The study
has also received clinical trial authorisation from the
Medicines and Healthcare products Regulatory Agency
(MHRA) (EudraCT number: 2010-023571-26). Appro-
priate approvals are in place for the Australian site. The
study conforms with the principles of the Declaration of
Helsinki and the European Clinical Trials Directive.
Strengths and weaknesses of this study
This is the first multi-centre, randomised, placebo-
controlled and double-blinded trial of sodium nitrite as
a conditioning agent in man. We use a robust method of
accurately delineating infarct size and area at risk using
CMR imaging techniques alongside the standard use of
biomarkers. Due to the risk of methaemoglobinaemia in
patients at risk of G6PD deficiency, only those of North-
ern European descent will be recruited. Further studies
need to be conducted in other ethnic groups.
Conclusion
Whilst huge strides have been made to reduce myocardial
infarct size by timely opening of the infarct related artery,
firstly ischemia and subsequently reperfusion itself cause
substantial myocardial injury. Effective therapy to reduce
this injury is urgently required if we are to make further
progress in limiting infarct size, thereby reducing the
subsequent development of heart failure. Whilst soundly
based on animal studies, this proposal would be the first
in man study to investigate whether intravenous infusion
of sodium nitrite reduces myocardial infarct size.
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